MedPage TodayAdjuvant Anti-PD-1 Misses on OS in High-Risk Melanoma

Dr. Kenneth Grossmann commented after presenting the results at the ASCO Annual Meeting in June: “The overall survival impact of pembrolizumab was likely influenced by effective post-relapse treatment, with standard-of-care patients receiving PD-1 blockade.” Dr. Grossmann then concluded that “single-agent anti-PD-1 antibody treatment should be a standard-of-care option for adjuvant treatment of high-risk resected melanoma,” and offered that the OS “trend of benefit is there.”